Effect of Spironolactone and dbcAMP-Ca Combination Therapy on Clinical Outcomes and Left Ventricular Function in Chronic Heart Failure Patients Post Percutaneous Coronary Intervention.

BACKGROUND: Improving treatment outcomes in chronic heart failure (CHF) patients post percutaneous coronary intervention (PCI) is of significant importance. CHF is a prevalent and severe chronic condition that negatively impacts patients' quality of life and increases the risks of hospitalization and mortality. Therefore, evaluating effective treatment strategies is crucial in improving the prognosis of CHF patients after PCI.

OBJECTIVE: The main objective of this study was to evaluate the clinical efficacy of combining spironolactone with dbcAMP-Ca in CHF patients following PCI. The study aimed to assess the impact of this combination therapy on both clinical outcomes and left ventricular function.

METHODOLOGY: The study design involved the random assignment of 110 CHF subjects post-PCI into two groups: a combination group receiving spironolactone with dbcAMP-Ca and a spironolactone-only group. The subjects' clinical efficacy, left ventricular function, plasma brain natriuretic peptide (BNP), serum uric acid (UA), serum high-sensitivity C-reactive protein (hs-CRP) levels, autonomic nerve function, and postoperative adverse reactions were assessed.

RESULTS: The results demonstrated that the combination group, receiving spironolactone with dbcAMP-Ca, showed superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function compared to the spironolactone-only group. Additionally, the combination group exhibited a lower incidence of adverse reactions and reduced levels of plasma BNP, UA, and hs-CRP. These findings indicate that spironolactone combined with dbcAMP-Ca has a favorable clinical effect in CHF patients post-PCI, effectively improving left ventricular and autonomic nerve function while maintaining high safety.

CONCLUSIONS: The combination therapy of spironolactone and dbcAMP-Ca holds potential as an effective treatment strategy for CHF patients following PCI. This combination therapy demonstrated superior clinical efficacy, improved left ventricular function, and enhanced autonomic nerve function, with reduced adverse reactions and biomarker levels. Spironolactone combined with dbcAMP-Ca can be considered as a beneficial treatment strategy for CHF patients post-PCI. The demonstrated clinical efficacy, improvement in left ventricular function, and enhanced autonomic nerve function support the wider application of this combination therapy in the management of CHF patients in clinical settings.